VIENNA, Sept 17 (Reuters) - Eli Lilly's (LLY.N), opens new tab bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed ...

Weight-loss with Lilly's GLP-1 pill plateaus for most patients Orforglipron improves cardiovascular risk factors, reduces inflammation marker by 47.7% High-dose orforglipron group sees 10.3% dropout ...

Eli Lilly has built a track record of growth thanks to a wide variety of drugs, but one portfolio in particular may drive gains a few years from now. The company already is a leader in the weight-loss ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.

i Controlled for family-wise type 1 error rate. ii Percentage of participants achieving body weight reductions of ≥20% with orforglipron 6 mg was not controlled for ...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading ...

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a ...

The U.S. FDA has issued separate warning letters to Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) regarding claims made about their obesity drugs in an Oprah Winfrey video special. The video, "An Oprah ...

VIENNA (Reuters) - Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and the company reaffirmed that it was too soon to assume ...